EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exploiting the DNA Damage Response for Prostate Cancer Therapy

Travis H Stracker iD, Oloruntoba I Osagie iD, Freddy E Escorcia iD, Deborah E Citrin iD

Cancers · 23.12.2023 · 16 (1) · 83

DOI: 10.3390/cancers16010083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.12.2023. Verfasst von Travis H Stracker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 313 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIH HHS, NCI-NIH intramural funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancers that progress despite androgen deprivation develop into castration-resistant prostate cancer, a fatal disease with few treatment options. In this review, we discuss the current understanding of prostate cancer subtypes and alterations in the DNA damage response (DDR) that can predispose to the development of prostate cancer and affect its progression. We identify barriers to conventional treatments, such as radiotherapy, and discuss the development of new therapies, many of which target the DDR or take advantage of recurring genetic alterations in the DDR. We place this in the context of advances in understanding the genetic variation and immune landscape of CRPC that could help guide their use in future treatment strategies. Finally, we discuss several new and emerging agents that may advance the treatment of lethal disease, highlighting selected clinical trials.

Schlagwörter

Stichwörter der Autor:innen

ATMATRDNA damage responseDNA-PKPARPandrogenhypoxiaimmunotherapyprostate cancerradiopharmaceutical therapyradiotherapy

Autor:innen und Institutionen

  • Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Travis H Stracker, Oloruntoba I Osagie, Freddy E Escorcia, Deborah E Citrin

Förderung

  • Intramural NIH HHS
  • NIH HHS
  • NCI-NIH intramural funding

Zitieren

APA

Stracker, T. H., Osagie, O. I., Escorcia, F. E., & Citrin, D. E. (2023). Exploiting the DNA Damage Response for Prostate Cancer Therapy. Cancers, 16(1), 83. https://doi.org/10.3390/cancers16010083

Vancouver

Stracker TH, Osagie OI, Escorcia FE, Citrin DE. Exploiting the DNA Damage Response for Prostate Cancer Therapy. Cancers. 2023;16(1):83. doi:10.3390/cancers16010083

BibTeX
@article{Stracker2023,
  author = {Stracker, Travis H and Osagie, Oloruntoba I and Escorcia, Freddy E and Citrin, Deborah E},
  title = {Exploiting the DNA Damage Response for Prostate Cancer Therapy},
  journal = {Cancers},
  year = {2023},
  volume = {16},
  number = {1},
  pages = {83},
  doi = {10.3390/cancers16010083}
}
Kostenlos starten →